Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThg Regulatory News (THG)

Share Price Information for Thg (THG)

Share Price is delayed by 15 minutes
Get Live Data
33.36    0.36 (1.09%)
Bid:
33.16
Ask:
33.42
Spread: 0.26 (0.784%)
Market Cap: £529.37m
THG Live PriceLast checked at - London Stock Exchange

Intraday Thg Share Chart

Share Purchase

17 Oct 2022 17:56

RNS Number : 1688D
THG PLC
17 October 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

 

17 October 2022

 

THG PLC

 

Share purchase

 

Sale of entire Softbank shareholding to each of QIA and Founder & CEO Matthew Moulding

 

 

THG PLC ("THG" or the "Group"), the proprietary technology platform specialising in taking brands direct to consumers globally, has today been informed that SB Northstar LP ("Softbank") has agreed to sell 80,621,797 ordinary shares of £0.005 each in the capital of THG (the "Relevant Shares"), representing its entire shareholding in THG, to each of Qatar Holding, LLC ("QIA") and Matthew Moulding (through FIC Shareco Limited ("FIC Shareco"), a PCA of Matthew Moulding) in the following proportions: 67,801,285 to QIA and 12,820,512 to FIC Shareco.

 

The Relevant Shares are to be sold at a price of 39 pence per share and settlement of the sale is expected to take place on 20 October 2022, following which the relevant notifications are expected to be made in accordance with the Disclosure Guidance and Transparency Rules and the Market Abuse Regulation 596/2014 as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018.

 

QIA is an existing shareholder, having cornerstoned THG's initial public offering in September 2020, with deep expertise in retail, consumer and technology and a focus on growth opportunities which have a positive impact.

 

This acquisition by FIC Shareco on behalf of Matthew Moulding further evidences his commitment to the Group and its strategy, and is his fourth investment in THG since IPO, with over £38m invested in August 2021, July 2022 and October 2022. This purchase will take his direct and indirect holding to a total of 320,934,183 shares in THG, comprised of 198,744,095 ordinary voting shares and 122,190,088 unlisted ordinary shares, in each case of £0.005 in the capital of THG.

 

 

Matthew Moulding, CEO commented:

"I'm delighted to be further increasing my family's stake in THG, continuing our unswerving support following on from other recent share purchases. QIA shares the Board's vision of the scale of opportunity for THG, building a British global success story in large and growing addressable markets. QIA's long-term investment approach is a positive endorsement for the UK as a whole.

 

"I'm incredibly proud of the progress the team continue to make in each of our major divisions, and believe the uncertain macro-conditions provide an even greater opportunity for THG to further disrupt global Beauty, Nutrition and Technology markets.

 

"We at THG extend our thanks to Softbank for their support as a financial and commercial partner, and we will continue to benefit from the relationships formed across their international technology portfolio."

 

For further information please contact:

THG PLC

James Pochin, General Counsel and Company Secretary

 

James.Pochin@thehutgroup.com

 

Media enquiries:

 

Powerscourt - Financial PR adviser

Tel: +44 (0) 20 7250 1446

Victoria Palmer-Moore/Nick Dibden/Nick Hayns

thg@powerscourt-group.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKOBPABDDNKD
Date   Source Headline
22nd May 20267:00 amRNSNotice of AGM
21st Apr 20267:00 amRNSTrading Statement
20th Apr 20264:45 pmRNSNotice of Q1 Trading Update
8th Apr 20267:00 amRNSAnnual Report & Accounts 2025
26th Mar 20267:00 amRNSPreliminary FY 2025 results
25th Mar 20264:54 pmRNSNotice of Results
24th Feb 20267:45 amRNSPDMR/PCA Shareholding & TR-1 Notification
12th Feb 20267:00 amRNS-RMyprotein licensing partnership with Greencore
2nd Feb 20267:00 amRNSTotal Voting Rights
27th Jan 20263:49 pmRNSTR-1: Notification of major holdings
27th Jan 20263:45 pmRNSTR-1: Notification of Major Holdings
23rd Jan 20262:52 pmRNSTR-1: Notification of Major Holdings
22nd Jan 20263:00 pmRNSApplication for Listing and Total Voting Rights
16th Jan 20267:00 amRNSChange to Board Committee Membership
13th Jan 20267:00 amRNSQ4 2025 Trading Statement
12th Jan 20264:40 pmRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
16th Dec 20255:50 pmRNSTR-1: Notification of Major Holdings
9th Dec 20254:35 pmRNSTR-1: Notification of Major Holdings
9th Dec 202510:55 amRNSTR-1: Notification of Major Holdings
9th Dec 20259:15 amRNSPDMR/PCA Shareholding & TR-1 Notification
5th Dec 202510:15 amRNSDirector Declaration
5th Dec 202510:05 amRNSAdmission of Convertible Loan Shares and TVR
26th Nov 20259:45 amRNSPDMR/PCA Shareholdings
17th Nov 20257:00 amRNS-RMyprotein joins forces with Mars
3rd Nov 20257:00 amRNSBlock listing Interim Review
28th Oct 202511:14 amRNSDirector Declaration
14th Oct 20257:00 amRNSQ3 2025 Trading Statement
10th Oct 20257:00 amRNSNotice of Trading Update
19th Sep 20256:00 pmRNSOcean Wilsons
11th Sep 20257:00 amRNSInterim results for half-year ended 30 June 2025
10th Sep 20254:45 pmRNSNotice of Interim Results
5th Sep 20257:00 amRNSNotification under UKLR 6.4.9R(2)
6th Aug 20257:42 amRNSDisposal, H1 trading and Nutrition update - Amend
6th Aug 20257:00 amRNSDisposal, H1 trading and Nutrition update
9th Jul 20252:24 pmRNSChanges to Directors’ Responsibilities
25th Jun 20252:38 pmRNSResult of AGM
25th Jun 20257:00 amRNSAGM Trading Statement
5th Jun 20253:56 pmRNSTR-1: Notification of Major Holdings
23rd May 20257:00 amRNSNotice of AGM
1st May 20257:00 amRNSBlock Listing Six Monthly Return
30th Apr 20257:00 amRNSAnnual Report & Accounts 2024
29th Apr 20257:00 amRNSFY 2024 results and Q1 trading statement
23rd Apr 20257:00 amRNSResponse to media speculation
16th Apr 20254:45 pmRNSTR-1: Notification of Major Holdings
4th Apr 202510:30 amRNSTR-1: Notification of Major Holdings
4th Apr 20257:00 amRNSCompletion of debt refinancing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.